

ASX Release

WESTCOAST LAUNCHES NOVEL HEMOSTYP® GAUZE FOLLOWING TGA APPROVAL

PERTH, AUSTRALIA - 15 January 2014: SUDA LTD (ASX: SUD) today announces that its subsidiary, Westcoast Surgical and Medical Supplies (Westcoast), has launched a novel patented wound healing gauze, HemoStyp®, in Australia. This follows the recent approval of the gauze by the Australian Therapeutic Goods Administration (TGA). Westcoast is the exclusive distributor of HemoStyp® in Australia, New Zealand, New Guinea and the Pacific Islands.

HemoStyp® is a unique haemostatic gauze that is specifically formulated to aid in the process of haemostasis (clotting) when positioned on a wound or cut. It has been shown to stop bleeding more rapidly than alternative products and, unlike other gauzes, HemoStyp® is hypoallergenic and contains no potentially harmful chemicals or animal by-products. The HemoStyp® gauze was developed and is manufactured by the US company, United Health Products, Inc (OTCQB: UEEC).

Westcoast will initially focus on marketing the range of HemoStyp® gauzes in Western Australia through its established channels, including public and private hospitals, aged care, police and emergency services, government agencies including jails and detention centres, chemist and dental outlets and veterinary. In addition, Westcoast will be targeting the Australian Armed Forces as a potential major customer for the HemoStyp® gauze products.

Stephen Carter, CEO of SUDA LTD, commented: "HemoStyp® is a unique wound dressing with real advantages over other gauze products. We are excited to be launching this new product range as the exclusive distributor in Australia and other countries. HemoStyp® has the potential to make a materially positive impact on the net profit of our subsidiary Westcoast."

Further information: STEPHEN CARTER DIRECTOR SUDA LTD

NOTES TO EDITORS:

About SUDA LTD

SUDA LTD (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using novel formulations of existing off-patent pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (ie: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's most advanced product is a novel sub-lingual treatment, ArTiMistTM, for severe malaria in children. In a Phase III trial, ArTiMistTM was shown to be superior to intravenous quinine. Other development stage products include orals sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting and erectile dysfunction.

About Westcoast

Westcoast Surgical and Medical Supplies Pty Ltd is a fully owned subsidiary of SUDA LTD, which provides medical supplies to West Australian leading hospitals, aged care facilities, pharmacies, mining companies and other healthcare providers.

About HemoStyp®

HemoStyp® is an all-natural product comprised of regenerated oxidized cellulose gauze which is specifically formulated to aid in the process of haemostasis (clotting) when positioned on a cut or wound. HemoStyp® stops bleeding faster than ordinary gauze and is a more effective alternative. Unlike the other products in the wound care market, HemoStyp® contains no potentially harmful chemicals or animal by-products and is hypoallergenic. Once it has completed its task, HemoStyp® gauze is easily removed by dissolving it in water or saline solution. This method of removal neither disturbs the clotted surface nor encourages re-bleeding.